1. Scrip
  2. >>Business
  3. >>Deals
  4. >>Deal Watch

Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus

 
• By Joseph Haas and Mary Jo Laffler

Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.

Deal Watch 2021
• Source: Shutterstock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Bristol Myers Squibb Company inked a pair of technology collaborations on 4 October, with San Francisco protein degradation specialist...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal Watch

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, and Lisa Takagi

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

More from Deals